Welcome + the State of Sickle Cell Disease

Universal Access to High Quality Sickle Cell Disease Care: Are We There Yet?

The Patient Symposium: Managing Pain, Sleep, and Health-Related Quality of Life

Investigational New Drug, Device, and Therapeutics Symposium

"Is Wall Street Still Interested in Sickle Cell Disease?"

2023 Scientific Chair Welcome

Top Oral Abstract Presentations

Organ Damage and other Cardiac Diseases in Sickle Cell Disease Educational Session

Historical Trauma: Providing trauma informed care to patients with SCD

Curative Options in Sickle Cell Disease Plenary Session

Scientific Keynote: Reverse Implementation: What Can We Learn from our Ghanaian and Nigerian Colleagues About Managing Sickle Cell Disease in the United States?

An Update on Sickle Cell Disease from Federal Agencies

Dr. Kwaku "KOF" Ohene-Frempong East Meets West Global Sickle Cell Disease Symposium

Testing a Tailored Digital Mental Health Program for Sickle Cell Disease

Psychosocial Factors in Sickle Cell: Depression is associated with pain and opioid misuse among adults with sickle cell disease

A patient's perspective to addressing challenges at Emergency Departments (EDs) through a faithbased education forum

Using animations and graphical body image for assessing pain in sickle cell disease

Access to Mental Health Services for Sickle Cell Patients using Multidisciplinary Clinic

Building a Collaborative Culture among Northeast Sickle Cell Community-Based Organizations

Role of Red Cell Exchange and Restricted Opioid Care Plan in Reducing Hospitalization

Targeting sickle cell pathobiology and pain with novel transdermal curcumin

Palmitoylethanolamide modulates gait and hyperalgesia in sickle mice

PB-04 Reduces Multi-Organ Pathology & Hydroxyurea-Associated Cytopenias in Transgenic Sickle Mice

Arginine Therapy for Children with Sickle Cell Disease-Pain: A Randomized Controlled Trial

Low arginine bioavailability and clinical outcomes in children with sickle cell pain

Impact of IV Contrast Exposure during Vaso-occlusive Crisis on Sickle Cell Disease (SCD)

Biomarker Response to Administration of Adakveo in a “Real World” Clinical Setting

Leg Ulcer Prevalence and Outcomes in a Real-World Study of Patients Treated with Voxelotor

Interim Safety and Efficacy of Voxelotor in Children Aged 2 to <4 years With Sickle Cell Disease

Pain Sensitivity and Centralized Pain in Adults with Sickle Cell Disease and Controls

Trial in Progress: Phase 1b CROSSWALK-a Trial – Crovalimab for Acute Vaso-Occlusive Episodes in SCD

ASCENT1: A Phase 2 Trial to Evaluate the Efficacy and Safety of Oral Decitabine–Tetrahydrouridine (NDec) in Patients with Sickle Cell Disease

Efficacy and Safety of Exagamglogene Autotemcel for Sickle Cell Disease

Exploring Traumatic Injury Rates in Sickle Cell Disease Patients: A US Geographic Analysis

Hibiscus-Kids: A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease